Here's another boring abstract but I'd like to know. Are the authors saying that there are probably more infections resulting from taking Ocrevus than from Rituxan?
Or are they saying that the methods for reporting adverse events for the two drugs are different and the results may be skewed so that the infection rate looks higher for Ocrevus than for Rituxan (but might not really be higher)?
From Multiple Sclerosis Journal (August 24, 2020)--"Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database":
Only registered and activated users can see links., Click Here To Register...
Or are they saying that the methods for reporting adverse events for the two drugs are different and the results may be skewed so that the infection rate looks higher for Ocrevus than for Rituxan (but might not really be higher)?
From Multiple Sclerosis Journal (August 24, 2020)--"Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database":
Only registered and activated users can see links., Click Here To Register...

Comment